Prognostic Value of Malondialdehyde (MDA) in the Temporal Progression of Chronic Spinal Cord Injury

• Published in: Journal of personalized medicine Vol. 13; no. 4; p. 626
• Main Authors: Haro Girón, Sergio, Monserrat Sanz, Jorge, Ortega, Miguel A, Garcia-Montero, Cielo, Fraile-Martínez, Oscar, Gómez-Lahoz, Ana M, Boaru, Diego Liviu, de Leon-Oliva, Diego, Guijarro, Luis G, Atienza-Perez, Mar, Diaz, David, Lopez-Dolado, Elisa, Álvarez-Mon, Melchor
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2023; MDPI
• Subjects: Apoptosis; Biomarkers; By products; Colorimetry; Cytokines; Evolution; Fatty acids; Free radicals; Inflammation; Lipid peroxidation; Lipids; Malondialdehyde; malondialdehyde (MDA); Medical prognosis; Medical research; Medicine, Experimental; Neurons; Oxidative stress; Pathogenesis; plasma biomarker; Plasma levels; Precision medicine; Prognosis; Spinal cord injuries; spinal cord injury (SCI); Taiwan; Spain; plasma biomarker; lipid peroxidation; prognosis; malondialdehyde (MDA); oxidative stress; spinal cord injury (SCI)
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm13040626

Oxidative stress is a major signature of spinal cord injury (SCI). The altered levels of various oxidative stress markers have been demonstrated in acute and chronic SCI. However, the variation of these markers in patients with chronic SCI depending on the time since the initial injury has not been explored yet. Our aim was to measure plasma levels of malondialdehyde (MDA), a marker of lipid peroxidation in patients with SCI stratified in different periods of suffering the injury (0-5 years, 5-10 years, and more than 10 years). This cross-sectional study enrolled patients with SCI (N = 105) from different periods of the lesion and healthy control (HC) subjects (N = 38): short period (SCI SP, N = 31, time of evolution less than 5 years); early chronic (SCI ECP, N = 32, time of evolution 5-15 years); and late chronic (SCI LCP, N = 42, time of evolution more than 15 years). The plasma levels of MDA were measured using a commercially available colorimetric assay. Patients with SCI had significantly higher plasma levels of MDA than HC subjects. Receiver operating characteristic (ROC) curve analysis for plasma MDA levels in patients with SCI demonstrated areas under the curve (AUC) of 1 (HC vs. SCI-SP); 0.998 (HC vs. SCI-ECP); and 0.964 (HC vs. SCI-LCP). Additionally, three ROC curves were used to compare the different concentrations of MDA between the subgroups of patients with SCI, and the resulting AUCs were: 0.896 (SCI-SP vs. SCI-ECP); 0.840 (SCI-ECP vs. SCI-LCP); and 0.979 (SCI-SP vs. SCI-LCP). Plasma concentration of MDA can be considered as an oxidative stress biomarker to assess the prognosis of SCI in chronic stages.